Most patients on neuroleptic therapy experience extrapyramidal symptoms in one form or another during treatment. While the risk of extrapyramidal symptoms appears diminished with the newer and “atypical” neuroleptics (for example, risperidone, remoxipride, clozapine), it is not eliminated. It is essential that the treating clinician monitor for such side effects since if they are left untreated they can be an ongoing source of discomfort to the patient and may affect compliance with therapy. Antiparkinsonian medication represents the mainstay of treatment for neuroleptic-induced extrapyramidal symptoms. Their clinical use is reviewed here with reference to mode of action, indications, choice, side-effects and precautions.
References
1.
LangA.E., BlairR.D.G.Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. In: CalneD.B., ed. Drugs for the Treatment of Parkinson's Disease.Berlin: Springer-Verlag,1989.
2.
ModellJ.G., TandonR., BeresfordT.P.Dopaminergic activity of the antimuscarinic antiparkisonian agents.J Clin Psychopharmacol1989; 9: 347–351.
3.
TuneL., CoyleJ.T.Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects.Arch Gen Psychiatry1980; 37: 293–297.
4.
SnyderS., YamamuraH.Antidepressants and the muscarinic acetylcholine receptor.Arch Gen Psychiatry1977; 34: 236–239.
5.
AvissarS., SchreiberG.Muscarinic receptor subclassification and G-proteins: significance for lithium action in affective disorder and for the treatment of the extrapyramidal side effects of neuroleptics.Biol Psychiatry1989; 26: 113–130.
6.
OwenR.T.The role of anticholinergic drugs in treating neuroleptic-induced movement disorders.Drugs of Today1982; 18: 87–97.
7.
KruseW.Treatment of drug-induced extrapyramidal symptoms.Dis Nerv Syst1960; 21: 79–81.
8.
ChildersR.T.Procyclidine and benztropine methanesulfonate compared in drug-induced extrapyramidal reactions.Am J Psychiatry1962; 112: 462–463.
9.
EkadawiM.Y., FowkeR.P.A controlled trial of antiparkinson drugs in drug-induced parkinsonism.Br J Psychiatry1966; 112: 633–636.
10.
MerrickE.M., SchmittP.P.A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).Curr Ther Res1973; 15: 552–558.
11.
KellyJ.T., ZimmermanR.L., AbuzzahabF.S.A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.Pharmacology1974; 12: 65–73.
12.
AnanthJ., SanganiH., NoonanJ.P.A.Amantadine in drug-induced extrapyramidal signs: a comparative study.Int J Clin Pharmacol1975; 11: 323–326.
13.
DiMascioA., BernardoD.L., GreenblattD.J.A controlled trial of amantadine in drug-induced extrapyramidal disorders.Arch Gen Psychiatry1976; 33: 599–602.
14.
BraudeW.M., BarnesT.R., GoreS.M.Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions.Br J Psychiatry1983; 143: 139–150.
15.
FannW.E., LakeC.R.Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism.Am J Psychiatry1976; 133: 940–943.
16.
GagratD., HamiltonJ., BelmakerR.H.Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia.Am J Psychiatry1978; 135: 1232–1233.
17.
GelenbergA.J.Amantadine in the treatment of benztropine-refractory extrapyramidal disorders induced by antipsychotic drugs.Curr Ther Res1978; 22: 375–380.
18.
ChouinardG., AnnableL., Ross-ChouinardA.Ethopropazine and benztropine in neuroleptic-induced parkinsonism.J Clin Psychiatry1979; 40: 147–152.
19.
MagnusR.V.A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug-induced parkinsonism.J Int Med Res1980; 8: 343–346.
20.
FriisT., ChristensenR., GerlachJ.Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia.Acta Psychiatr Scand1983; 67: 176–187.
21.
ZubenkoG.S., LipinskiJ.F., CohenB.M.Comparison of metoprolol and propranolol in the treatment of akathisia.Psychiatry Res1984; 11: 143–149.
22.
McEvoyJ.P., McCueM., FréterS.Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.Clin Ther Res1987; 9: 429–433.
23.
AlderL.A., ReiterS., CorwinJ.Differential effects of propranolol and benztropine in patients with neuroleptic-induced akathisia.Psychopharmacol Bull1987; 23: 519–521.
24.
Van PuttenT., MayP.R.A., MarderS.R.Akathisia with haloperidol and thiothixene.Arch Gen Psychiatry1984; 41: 1026–1039.
FayenM., GoldmanM.B., MoulthropM.A.Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.Am J Psychiatry1988; 145: 483–486.
33.
GelenbergA.J., Van PuttenT., LavoriP.W.Anticholinergic effects on memory: benztropine versus amantadine.J Clin Psychopharmacol1989; 9: 180–185.
34.
McEvoyJ.P., McCueM., SpringB.Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers.Am J Psychiatry1987; 144: 573–577.
35.
PotamianosG., KellettJ.M.Anticholinergic drugs and memory: the effects of benzhexol on memory in a group of geriatric patients.Br J Psychiatry1982; 140: 470–472.
36.
WarnesH.Toxic psychosis due to antiparkinsonian drugs.Can Psychiatr Assoc J1967; 12: 323–326.
GranacherR.P., BaldessariniR.J.Physostigmine: its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs.Arch Gen Psychiatry1975; 32: 375–380.
39.
GreilW., HaagH., RossnaglG.Effect of anticholinergics on tardive dyskinesia: a controlled discontinuation study.Br J Psychiatry1984; 145: 304–310.
40.
JellinekT., GardosG., ColeJ.O.Adverse effects of antiparkinson drug withdrawal.Am J Psychiatry1981; 138: 1567–1571.
41.
BriggsG.G., FreemanR.K., YaffeS.J.Drugs in pregnancy and lactation, third edition.Baltimore: Williams & Wilkins,1990: 15, 58, 64.
42.
TatroD.S., ed. Drug interaction facts.St. Louis MO: Facts and Comparisons, 1993.
43.
Bezchlibnyk-ButlerK., JeffriesJ.J., eds. Clinical handbook of psychotropic drugs.Toronto ON: Hogrefe & Huber, 1991.
44.
AydF.J.Abuse of anticholinergic drugs: an under-recognized problem.Int Drug Ther Newsletter1985; 20: 1–2.
45.
BrowerK.S.Smoking of prescription anticholinergic drugs.Am J Psychiatry1987; 144: 383.
46.
World Health Organization.Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement.Br J Psychiatry1990; 156: 412.
47.
BarnesT.R.E.Comment on the WHO consensus statement.Br J Psychiatry1990; 156: 413–414.
48.
KaneJ.M., WoernerM., WeinholdP.Incidence of tardive dyskinesia: five-year data from a prospective study.Psychopharmacol Bull1984; 20: 39–40.
49.
ChouinardG., AnnableL., Ross-ChouinardA.A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.J Clin Psychopharmacol1988; 8: 22S–26S.
50.
YassaR.Tardive dyskinesia and anticholinergic drugs: a critical review of the literature.L'Encephale1988; 14: 233–239.
51.
YassaR.Antiparkinsonian medication withdrawal in the treatment of tardive dyskinesia: a report of three cases.Can J Psychiatry1985; 30: 440–441.
52.
ChouinardG., SteinbergS.Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics.Prog Neuro-psychopharmacol & Biol Psychiatry1982; 6: 571–578.
53.
BurnettG.B., PrangeA.S.Jr, WelsaI.C.Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia.Neuropsychobiology1980; 6: 109–120.
54.
Bolvig HansenL., ElleyJ., Rosted ChristensenT.Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs.Br J Clin Pharmacol1979; 7: 75–80.
55.
GautierJ., JusA., VilleneuveA.Influence of the antiparkinsonian drugs on the plasma level of neuroleptics.Biol Psychiatry1977; 12: 389–399.
56.
TandonR., MannN.A., EisnerW.H.Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients.Psychiatr Res1989; 31: 235–241.
57.
TandonR., GredenI.J.F., SelkK.R.Treatment of negative schizophrenic symptoms with trihexyphenidyl.J Clin Psychopharmacol1988; 8: 212–221.
58.
WilcoxJ.A., TsuangJ.Psychological effects of amantadine on psychotic subjects.Neuropsychobiology1990; 23: 144–146.
59.
AthanassenasG., PapadopoulosE., KourkoubasA.Serum calcium and magnesium levels in chronic schizophrenics.J Clin Psychopharmacol1983; 3: 212–216.
PrattyJ.S., AnanthJ., O'BrienJ.E.Relationship between dystonia and serum calcium levels.J Clin Psychiatry1986; 47: 418–419.
62.
BrownK.W., GlenS.E., WhiteT.Low serum iron status and akathisia.Lancet1987; 8450: 1234–1236.
63.
BartonA., BowieJ., EbmeierK.Low plasma iron status and akathisia.J Neurol Neurosurg Psychiatry1990; 53: 671–674.
64.
HoreguchiJ.Low serum iron in patients with neuroleptic-induced akathisia and dystonia under antipsychotic drug treatment.Acta Psychiatr Scand1991; 84: 301–303.
65.
CedarbaumJ.M.Clinical pharmacokinetics of antiparkinsonian drugs.Clin Pharmacokinet1987; 13: 141–178.
66.
SnyderS., GreenbergD., YamamuraH.I.Antischizophrenic drugs and brain cholinergic receptors.Arch Gen Psychiatry1974; 31: 58–61.
